asymptomatic stenosis (41 [51%]). The perioperative complications were few and similar between groups (bleeding, infection, immediate occlusion, and stroke). Patency rates, as determined by duplex ultrasound imaging, were similar at 1 year (100% VBG vs 99% PBG; P ¼ .434). The 5-to 10-year patency was also similar between groups (84% VBG vs 88% PBG; P ¼ .434; Fig) .
Objectives: In 2016, pancreatic cancer became the third leading cause of cancer-related death in the United States. While 5-year survival rates remain in the single digits, surgical resection offers the only potential for cure and can increase survival tenfold. As such, patients with portomesenteric vein involvement benefit from surgical resection with portomesenteric vein reconstruction (PVR). Studies demonstrate the feasibility of PVR with femoral and/or saphenous vein conduits; however, femoral vein (FV) harvest is associated with increased risk of deep vein thrombosis (DVT) and wound complications. Cryopreserved FV may be a reasonable alternative avoiding such morbidity. We sought to compare outcomes of autogenous vs cryopreserved FV conduit in patients undergoing PVR during pancreaticoduodenectomy.
Methods: This was a retrospective review of our National Surgical Quality Improvement Program database for all patients undergoing pancreaticoduodenectomy with PVR from January 2010 to July 2016. Patient demographics (age, sex, and comorbidities) and tumor stage and pathology records were assessed. Postoperative complications, conduit patency, and perioperative mortality were compared between autogenous and cryopreserved vein groups.
Results: A total of 48 patients, 26 autogenous and 22 cryopreserved vein, underwent PVR. Demographics were similar between groups, although the autogenous vein group consisted of significantly more patients with diabetes (48% vs 14%; P ¼ .015). Median follow-up was 6.7 months. Median survival was 24 months between both groups. Tumor stage did not differ significantly between groups. Conduit patency (Fig 1) and overall survival (Fig 2) did not differ between groups. While surgical site infection rates did not differ between the groups (7% v 0%; P ¼ .493), there was a significantly higher rate of perioperative DVT in the autogenous vein group (57% v 14%; P ¼ .002). These DVTs were notably more likely to be proximal to the site of FV harvest. There were no conduit infections in either group. Univariate analysis demonstrated autogenous vein conduit and diabetes mellitus were independent predictors of perioperative DVT.
Conclusions: Patients undergoing oncologic pancreatic resection with PVR do not have significantly different patency or survival rates regardless of the conduit used. Since autogenous vein harvest is associated with significantly higher rates of perioperative DVT, cryopreserved vein should be considered for all PVR in pancreatic resection as it avoids the morbidity associated with autogenous vein harvest. Objectives: This study reports the consequences of stenting across the renal vein confluence in patients undergoing caval reconstruction.
Methods: A total of 93 patients underwent venous stenting from June 2008 until September 2016: 54 (58%) were female and 39 (42%) were male, with a mean age of 39 years. Patients presented with lower extremity pain, swelling, or ulcers (n ¼ 48), deep venous thrombosis (n ¼ 42), or mass compressing the inferior vena cava (n ¼ 3). Patients received stents covering (n ¼ 39) or sparing (n ¼ 54) the renal veins. Stenting technical success, stent type, glomerular filtration rate (GFR), and creatinine before and after stenting, complications, and renal vein patency on follow-up imaging were recorded. For GRFs >60, 60 was used.
Results: All (100%) stenting procedures were successful. Patients who received Wallstent (n ¼ 15) or Z-stent (n ¼ 24) endoprostheses across the renal veins or were given a "renal gap" with no stent placement (n ¼ 12) were considered treatments. Patients receiving iliac vein stents only were considered controls (n ¼ 42). Renal functions were obtained at a mean of 12 days before stenting. Mean prestenting GFR (mL/min/ 1.73 m 2 ) and creatinine (mg/dL) were 59 (range, 51-60) and 0.8 (range, 0.4-1.2). Mean prestenting GFR and creatinine in the Wallstent, Z-stent, "renal gap," and iliac vein only stent patients were: 60 and 0.8, 59 and 0.9, 60 and 0.7, and 60 and 0.8, respectively. There were no differences in prestenting mean GFR or creatinine between the Wallstent (P ¼ .21; P ¼ .40), Z-stent (P ¼ .19; P ¼ .24), and "renal gap" (P ¼ .24; P ¼ .09), and the iliac vein only stent group. Renal functions were obtained at a 
